knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 05:38:27 - browse：217

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： The unintended consequences of overturning Roe v. Wade

WSS

PBMs drew scrutiny in House hearing — and so did pharma

For Medicare Advantage, Democrats want stronger protections around AI

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Readout LOUD podcast: How biotech is using artificial intelligence

Why the quest to eradicate polio has stumbled

Eli Lilly CEO gives to Mike Pence presidential super PAC

entertainment

knowledge

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Medicare threatens to cut off funding for HCA's Mission hospital

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Heart attack and stroke risk calculators need revising

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

How to save PrEP access — and even expand it

Senators start work on Medicare physician payment reform

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Midwives could help bridge maternal health disparities in the U.S.

focus

BioAge raises $170M for combination therapy with Zepbound

KalVista pill reduced swelling 'attacks' caused by genetic disease

Industry veterans launch new biotech VC with $310M

Patients, doctors press FTC to beef up hospital merger scrutiny

Medical mystery: When a cough is not just a cough

Vaccine advisory panel ACIP left half staffed by HHS

focus

focus

hotspot

Wikipedia